JP2025514745A5 - - Google Patents
Info
- Publication number
- JP2025514745A5 JP2025514745A5 JP2024561763A JP2024561763A JP2025514745A5 JP 2025514745 A5 JP2025514745 A5 JP 2025514745A5 JP 2024561763 A JP2024561763 A JP 2024561763A JP 2024561763 A JP2024561763 A JP 2024561763A JP 2025514745 A5 JP2025514745 A5 JP 2025514745A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- cells
- seq
- manipulated
- hla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263333035P | 2022-04-20 | 2022-04-20 | |
| US202263333036P | 2022-04-20 | 2022-04-20 | |
| US202263333031P | 2022-04-20 | 2022-04-20 | |
| US63/333,031 | 2022-04-20 | ||
| US63/333,036 | 2022-04-20 | ||
| US63/333,035 | 2022-04-20 | ||
| US202263392738P | 2022-07-27 | 2022-07-27 | |
| US63/392,738 | 2022-07-27 | ||
| US202263383805P | 2022-11-15 | 2022-11-15 | |
| US63/383,805 | 2022-11-15 | ||
| US202363478588P | 2023-01-05 | 2023-01-05 | |
| US63/478,588 | 2023-01-05 | ||
| PCT/US2023/065967 WO2023205705A2 (en) | 2022-04-20 | 2023-04-19 | Allogeneic t cells for treatment of hematological malignancies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025514745A JP2025514745A (ja) | 2025-05-09 |
| JP2025514745A5 true JP2025514745A5 (https=) | 2026-04-28 |
Family
ID=86330335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024561763A Pending JP2025514745A (ja) | 2022-04-20 | 2023-04-19 | 血液悪性腫瘍の治療のための同種ｔ細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250242021A1 (https=) |
| EP (1) | EP4511056A2 (https=) |
| JP (1) | JP2025514745A (https=) |
| KR (1) | KR20250006881A (https=) |
| CN (1) | CN119325389A (https=) |
| AU (1) | AU2023257377A1 (https=) |
| CA (1) | CA3249498A1 (https=) |
| IL (1) | IL316365A (https=) |
| WO (1) | WO2023205705A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025122271A1 (en) * | 2023-12-08 | 2025-06-12 | IN8bio, Inc. | Methods of allogeneic hematopoietic stem cell transplantation and cancer treatment |
| GB202318950D0 (en) * | 2023-12-12 | 2024-01-24 | Adaptimmune Ltd | Production of immune cells |
| AU2025202444A1 (en) * | 2024-04-08 | 2025-10-23 | Tscan Therapeutics, Inc. | Use of anti-ha-1 and anti-ha-2 binding proteins for treatment of aml, all, and mds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
| US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
-
2023
- 2023-04-19 JP JP2024561763A patent/JP2025514745A/ja active Pending
- 2023-04-19 AU AU2023257377A patent/AU2023257377A1/en active Pending
- 2023-04-19 WO PCT/US2023/065967 patent/WO2023205705A2/en not_active Ceased
- 2023-04-19 EP EP23722803.6A patent/EP4511056A2/en active Pending
- 2023-04-19 CN CN202380042403.XA patent/CN119325389A/zh active Pending
- 2023-04-19 IL IL316365A patent/IL316365A/en unknown
- 2023-04-19 KR KR1020247037302A patent/KR20250006881A/ko active Pending
- 2023-04-19 US US18/857,000 patent/US20250242021A1/en active Pending
- 2023-04-19 CA CA3249498A patent/CA3249498A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Diorio et al. | Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks | |
| JP2025514745A5 (https=) | ||
| JP6196620B2 (ja) | 抗第三者セントラルメモリーｔ細胞、その作製方法ならびに移植および疾患処置におけるその使用 | |
| JP7584437B2 (ja) | 抗ｂｃｍａ ｃａｒ ｔ細胞の製造 | |
| Biernacki et al. | T cell optimization for graft-versus-leukemia responses | |
| Saito et al. | Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1–specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: a case report and review of the literature | |
| JP2023139223A (ja) | 幹細胞移植のための非遺伝毒性移植前処置レジメン | |
| Bornhaeuser et al. | Prophylactic transfer of BCR-ABL–, PR1-, and WT1-reactive donor T cells after T cell–depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia | |
| US20250242021A1 (en) | Allogeneic t cells for treatment of hematological malignancies | |
| García et al. | Phase 2 clinical trial of infusing haploidentical K562-mb15-41BBL–activated and expanded natural killer cells as consolidation therapy for pediatric acute myeloblastic leukemia | |
| Van Caeneghem et al. | Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities | |
| Anam et al. | Amnion-derived multipotent progenitor cells support allograft tolerance induction | |
| WO2012146702A1 (en) | Methods for preparing accessory cells and uses thereof for preparing activated nk cells | |
| WO2013014535A1 (en) | Methods and compositions for enhancing t cell diversity | |
| JP2022515144A (ja) | オフザシェルフのダブルネガティブｔ細胞の産生および治療的使用 | |
| Levenga et al. | Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma | |
| Al Malki et al. | Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium—Haplo2014, San Francisco, California, December 4, 2014 | |
| Marin et al. | “Off the Shelf” CAR‐T/NK Cells | |
| Yu et al. | Alloreactive natural killer cells promote haploidentical hematopoietic stem cell transplantation by expansion of recipient‐derived CD4+ CD25+ regulatory T cells | |
| Cavazzana et al. | Beyond conventional adoptive T-cell therapy | |
| Guolo et al. | PS1535 AUTOLOGOUS STEM CELL TRANSPLANT FOLLOWED BY POST‐TRANSPLANT IMMUNOTHERAPY WITH NIVOLUMAB AND UNSELECTED AUTOLOGOUS LYMPHOCYTES INFUSION AS SALVAGE THERAPY FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA | |
| Abutalib et al. | Most Recent Clinical Advances in CAR T Cell and Gene Therapy 2017/2018 | |
| Stevanović | Exploiting HLA-class II disparity for anti-tumor immunity by allogeneic cellular | |
| Dazzi et al. | Oral Session: Graft engineering and Cellular therapy | |
| Zeis et al. | The immature laminin-receptor protein is a suitable target for immunotherapy against hematological malignancies |